Table 1.
Comparison of Clinicopathologic Features of Women With and Without Axillary Ultrasound and Women With and Without MRI
| Factor | No axillary US (n=183) |
Axillary US (n=242) |
p Value |
No MRI (n=253) | MRI (n=172) | p Value |
|---|---|---|---|---|---|---|
| Age, y, median (range) | 61.6 (30.6–92.1) | 55.6 (28.2–85.0) | 0.002 | 61.8 (31.5–92.1) | 53.2 (28.2–83.4) | <.0001 |
| Preoperative tumor size by imaging, cm, median (range) |
1.6 (0.08–5.8) | 1.8 (0.4–6.0) | 0.006 | 1.6 (0.08–6.0) | 1.8 (0.4–5.8) | 0.58 |
| Abnormal lymph nodes seen on mammogram, n (%) |
6 (3) | 25 (10) | 0.006 | 18 (7) | 13 (8) | 0.86 |
| Final pathologic tumor size, cm, median (range) |
1.6 (0.4–5.2) | 1.9 (0.1–5.2) | 0.009 | 1.8 (0.1–4.9) | 1.8 (0.3–5.2) | 0.87 |
| Tumor histology, n (%) | 0.33 | 0.91 | ||||
| Ductal | 151 (83) | 211 (87) | 216 (85) | 146 (85) | ||
| Lobular | 23 (13) | 20 (8) | 26 (10) | 17 (10) | ||
| Other | 9 (5) | 11 (5) | 11 (4) | 9 (5) | ||
| Nuclear grade, n (%) | 0.06 | 0.13 | ||||
| 1 | 20 (11) | 12 (5) | 14 (6) | 18 (10) | ||
| 2 | 97 (53) | 130 (54) | 137 (54) | 90 (52) | ||
| 3 | 61 (33) | 92 (38) | 96 (38) | 57 (33) | ||
| NA | 5 (3) | 8 (3) | 6 (2) | 7 (4) | ||
| Multifocal tumor, n (%) | 24 (13) | 32 (13) | 0.96 | 31 (12) | 25 (15) | 0.48 |
| LVI present, n (%) | 106 (58) | 144 (60) | 0.74 | 149 (59) | 101 (59) | 0.97 |
| ER status, n (%) | 0.41 | 0.86 | ||||
| Positive | 165 (90) | 212 (88) | 225 (89) | 152 (88) | ||
| Negative | 18 (10) | 30 (12) | 28 (11) | 20 (12) | ||
| PR status, n (%) | 0.40 | 0.73 | ||||
| Positive | 154 (84) | 196 (81) | 207 (82) | 143 (83) | ||
| Negative | 29 (16) | 46 (19) | 46 (18) | 29 (17) | ||
| HER2-neu status, n (%)* | 0.10 | 0.54 | ||||
| Positive | 38 (21) | 67 (28) | 60 (24) | 45 (26) | ||
| Negative | 144 (79) | 173 (72) | 192 (76) | 125 (74) | ||
| SLN microscopic ECE, n | 170 | 204 | 0.015 | 222 | 152 | 0.19 |
| Present, n (%) | 66 (39) | 55 (27) | 66 (30) | 55 (36) | ||
| Absent, n (%) | 104 (61) | 149 (73) | 156 (70) | 97 (64) |
*
Data missing for 3 patients.
US, ultrasound; NA, not available; LVI, lymphovascular invasion; ER, estrogen receptor; PR, progesterone receptor; SLN, sentinel lymph node; ECE, extracapsular extension.